Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs

• Status: Completed
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the lung's immune response to mycobacterium tuberculosis (Mtb) infection and will modulate that response with interferon-gamma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York University School of Medicine; NYU Langone Health
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Interferon-gamma; Interferons

Criteria

Inclusion Criteria:

• Positive acid-fast bacillus (AFB) smear within 14 days prior to randomization

• Cluster of Differentiation 4 greater than 200 if HIV positive

• Ability to sign consent

• Bilateral, cavitary pulmonary TB

Exclusion Criteria:

• Multidrug-resistant (MDR) TB

• Extrapulmonary TB

• HIV positive with opportunistic infection within 30 days of study entry

• Cancer

• Asthma

• Pregnant or lactating women

• Chronic heart disease

• Chronic liver disease

• Chronic renal disease

• Seizure disorder

• Bleeding or clotting disorder

• Diabetes mellitus